This Phase I study assessed the safety and efficacy of using MDMA-assisted psychotherapy to treat alcohol use disorder (AUD).
This open-label study (n=14) with MDMA-assisted psychotherapy (2 sessions;187.5mg) found it to be well-tolerated and safe to use.
Compound MDMA
Country United Kingdom
Visit trial
Status
Completed
Results Published
Yes
Start date
20 April 2020
End date
20 April 2021
Chance of happening
100%
Phase
Phase I
Design
Open
Type
Interventional
Generation
First
Participants
14
Sex
All
Age
18- 99
Therapy
No
Trial Details
NCT Number
Sponsors & Collaborators
Awakn Life SciencesAWAKN Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.
Imperial College London
The Centre for Psychedelic Research studies the action (in the brain) and clinical use of psychedelics, with a focus on depression.
Papers
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorderThis open-label study (n=14) with MDMA-assisted psychotherapy (2 sessions;187.5mg) found it well-tolerated and safe to use. The average consumption of alcohol nine months later was 18.7 units, versus 130.6 units before the detox (start of the study).